Use of medication for insomnia or anxiety increases mortality risk by 36 percent

	Tweet

Taking medications to treat insomnia and anxiety increases mortality risk by 36%, according to a study conducted by Geneviève Belleville, a professor at Université Laval’s School of Psychology. The details of this study are published in the latest edition of the Canadian Journal of Psychiatry.

Dr. Belleville arrived at these results through analysis of 12 years of data on over 14,000 Canadians in Statistics Canada’s National Population Health Survey. The data includes information on the social demographics, lifestyle, and health of Canadians age 18 to 102, surveyed every two years between 1994 and 2007.

During this period, respondents who reported having used medication to treat insomnia or anxiety at least once in the month preceding the survey had a mortality rate of 15.7%. Respondents who reported not having used such medications had a rate of 10.5%. After controlling for personal factors that might affect mortality risk, notably alcohol and tobacco consumption, physical health, physical activity level, and the presence or absence of depressive symptoms among participants, Dr. Belleville established that the consumption of sleeping pills or anxiety-relieving medications was associated with a 36% increase in the risk of death.

A number of hypotheses have been put forward to explain the link between use of these medications and increased mortality. Sleeping pills and anxiolytics affect reaction time, alertness, and coordination and are thus conducive to falls and other accidents. They may also have an inhibiting effect on the respiratory system, which could aggravate certain breathing problems during sleep. These medications are also central nervous system inhibitors that may affect judgment and thus increase the risk of suicide.

“These medications aren’t candy, and taking them is far from harmless,” commented Dr. Belleville. “Given that cognitive behavioral therapies have shown good results in treating insomnia and anxiety, doctors should systematically discuss such therapies with their patients as an option. Combining a pharmacological approach in the short term with psychological treatment is a promising strategy for reducing anxiety and promoting sleep.”

###

Information:
Geneviève Belleville
School of Psychology
Université Laval
(418) 656-2131 ext. 4226

Source:
Jean-François Huppé
Media Relations
Université Laval
(418) 656-7785

###

Contact: Jean-François Huppé

418-656-7785
Université Laval

RELATED STORIES:
Secretin not effective for autism   Drug commonly used for alcoholism curbs urges of pathological gamblers   Mothers with postpartum depression with suicidal thoughts and their infant interactions   Bullying victims have more psychotic symptoms   Short breast-feeding linked to later alcoholism   Mental problems hit over 1,000 UK troops after Iraq   Children of Older Fathers More Likely to Have Bipolar Disorder   A pioneering study opens roads for tailor-made antidepressants   Nightmares and Night Terrors in Children   Depression, anxious personality tied to allergies   Heart, respiration rates predict PTSD risk   Is Post-Stroke Depression Different from Post-MI Depression?   Recognition and Treatment of Depression and Anxiety Symptoms in Heart Failure   What happens to baby when Mom is depressed?   Depression often afflicts heart failure sufferers

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]